Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HB-0045 by Huabo Biopharm (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...